15 results on '"Winokur, Patricia"'
Search Results
2. Immunogenicity of the BA.1 and BA.4/BA.5 Severe Acute Respiratory Syndrome Coronavirus 2 Bivalent Boosts: Preliminary Results From the COVAIL Randomized Clinical Trial.
- Author
-
Branche, Angela, Rouphael, Nadine, Losada, Cecilia, Baden, Lindsey, Anderson, Evan, Luetkemeyer, Anne, Diemert, David, Winokur, Patricia, Presti, Rachel, Kottkamp, Angelica, Falsey, Ann, Frey, Sharon, Rupp, Richard, Bäcker, Martín, Novak, Richard, Walter, Emmanuel, Jackson, Lisa, Little, Susan, Immergluck, Lilly, Mahgoub, Siham, Whitaker, Jennifer, Babu, Tara, Goepfert, Paul, Fusco, Dahlene, Atmar, Robert, Posavad, Christine, Netzl, Antonia, Smith, Derek, Telu, Kalyani, Mu, Jinjian, Makowski, Mat, Makhene, Mamodikoe, Crandon, Sonja, Montefiori, David, Roberts, Paul, and Beigel, John
- Subjects
SARS-CoV-2 ,vaccine ,variant ,Humans ,COVID-19 ,SARS-CoV-2 ,Antibodies ,Neutralizing ,Vaccines ,Combined ,Antibodies ,Viral - Abstract
In a randomized clinical trial, we compare early neutralizing antibody responses after boosting with bivalent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) messenger RNA (mRNA) vaccines based on either BA.1 or BA.4/BA.5 Omicron spike protein combined with wild-type spike. Responses against SARS-CoV-2 variants exhibited the greatest reduction in titers against currently circulating Omicron subvariants for both bivalent vaccines.
- Published
- 2023
3. Priming Vaccination With Influenza Virus H5 Hemagglutinin Antigen Significantly Increases the Duration of T cell Responses Induced by a Heterologous H5 Booster Vaccination.
- Author
-
Hoft, Daniel F., Lottenbach, Kathleen, Goll, Johannes B., Hill, Heather, Winokur, Patricia L., Patel, Shital M., Brady, Rebecca C., Chen, Wilbur H., Edwards, Kathryn, Creech, C. Buddy, Frey, Sharon E., Blevins, Tamara P., Salomon, Rachelle, and Belshe, Robert B.
- Subjects
VACCINATION ,IMMUNIZATION ,HEMAGGLUTININ ,AGGLUTININS ,HEMAGGLUTINATION tests - Abstract
Background: Influenza A(H5N1) virus and other avian influenza virus strains represent major pandemic threats. Like all influenza A virus strains, A(H5N1) viruses evolve rapidly. Innovative immunization strategies are needed to induce cross-protective immunity.Methods: Subjects primed with clade 1 H5 antigen, with or without adjuvant, and H5-naive individuals were boosted with clade 2 H5 antigen. The impact of priming on T cells capable of both proliferation and cytokine production after antigen restimulation was assessed.Results: Subjects previously vaccinated with clade 1 H5 antigen developed significantly enhanced clade 2 H5 cross-reactive T cell responses detectable 6 months after vaccination with clade 2 H5 antigen. Priming dose (15 µg vs 45 or 90 µg) had no effect on magnitude of heterotypic H5 T cell responses. In contrast, age at priming negatively modulated both the magnitude and duration of heterotypic H5 T cell responses. Elderly subjects developed significantly less heterotypic H5 T cell boosting, predominantly for T cells capable of cytokine production. Adjuvant had a positive albeit weaker effect than age. The magnitude of CD4(+) interferon-γ producing T cells correlated with H5 antibody responses.Conclusions: H5 heterotypic priming prior to onset of an A(H5N1) pandemic may increase magnitude and duration of immunity against a newly drifted pandemic H5 virus. [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
4. Safety and Immunogenicity of Full-Dose Trivalent Inactivated Influenza Vaccine (TIV) Compared With Half-Dose TIV Administered to Children 6 Through 35 Months of Age.
- Author
-
Halasa, Natasha B., Gerber, Michael A., Berry, Andrea A., Anderson, Edwin L., Winokur, Patricia, Keyserling, Harry, Eckard, Allison Ross, Hill, Heather, Wolff, Mark C., McNeal, Monica M., Edwards, Kathryn M., and Bernstein, David I.
- Subjects
INFLUENZA vaccination research ,VACCINATION of children ,DRUG dosage ,IMMUNIZATION of children ,ANTIGENS - Abstract
Background. Children 6 through 35 months of age are recommended to receive half the dose of influenza vaccine compared with older children and adults. Methods. This was a 6-site, randomized 2:1, double-blind study comparing full-dose (0.5 mL) trivalent inactivated influenza vaccine (TIV) with half-dose (0.25 mL) TIV in children 6 through 35 months of age. Children previously immunized with influenza vaccine (primed cohort) received 1 dose, and those with no previous influenza immunizations (naive cohort) received 2 doses of TIV. Local and systemic adverse events were recorded. Sera were collected before immunization and 1 month after last dose of TIV. Hemagglutination inhibition antibody testing was performed. Results. Of the 243 subjects enrolled (32 primed, 211 naive), data for 232 were available for complete analysis. No significant differences in local or systemic reactions were observed. Few significant differences in immunogenicity to the 3 vaccine antigens were noted. The immune response to H1N1 was significantly higher in the full-dose group among primed subjects. In the naive cohort, the geometric mean titer for all 3 antigens after 2 doses of TIV were significantly higher in the 12 through 35 months compared with the 6 through 11 months age group. Conclusions. Our study confirms the safety of full-dose TIV given to children 6 through 35 months of age. An increase in antibody responses after full- versus half-dose TIV was not observed, except for H1N1 in the primed group. Larger studies are needed to clarify the potential for improved immunogenicity with higher vaccine doses. Recommending the same dose could simplify the production, storage, and administration of influenza vaccines. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
5. Safety and Immunogenicity of a Subvirion Monovalent Unadjuvanted Inactivated Influenza A(H3N2) Variant Vaccine in Healthy Persons #8805;18 Years Old.
- Author
-
Winokur, Patricia L., Patel, Shital M., Brady, Rebecca, Chen, Wilbur H., El-Kamary, Samer S., Edwards, Kathryn, Creech, C. Buddy, Frey, Sharon, Keitel, Wendy A., Belshe, Robert, Walter, Emmanuel, Bellamy, Abbie, and Hill, Heather
- Subjects
- *
H5N1 Influenza , *VIRUS diseases , *VIRAL disease treatment , *DRUG dosage , *HEMAGGLUTINATION tests , *PATIENTS , *VACCINATION - Abstract
Background. Variant influenza A(H3N2) viruses (H3N2v) have transmitted recently from pigs to humans in the United States. Vaccines strategies are needed. Methods. Healthy adults received 2 doses of subvirion H3N2v vaccine (15 μg of hemagglutinin/dose) 21 days apart in this open-label trial. Serum hemagglutination inhibition (HAI) and neutralizing (Neut) antibody (Ab) titers were measured before and 8 and 21 days after each dose. Memory B-cell (MBC) responses were assessed. Results. Vaccine was well tolerated. A total of 40% of subjects had an HAI Ab titer of ≥40 before vaccination. Eight-seven percent (95% confidence interval [CI], 79%-93%) and 73% (95% CI, 63%-81%) of subjects 18-64 years old (98 subjects) and ≥65 years old (90 subjects), respectively, had an HAI titer of ≥40 21 days after dose 1 (P = .01); 51% (95% CI, 41%-61%) and 52% (95% CI, 41%-62%) of younger and older subjects, respectively, developed ≥4- fold rises in titer (P = not significant). Neut Ab response patterns were similar. Geometric mean titers were higher in younger subjects. Dose 2 provided no significant enhancement in responses. Cross-reactive MBCs were detected before vaccination and expanded after vaccination. Preexisting H3N2v-specific MBCs positively correlated with early increases in vaccine-induced Ab. Conclusions. In most healthy adults, one 15-μg dose of vaccine elicited levels of HAI Abs associated with protection. Studies in children and elderly individuals are indicated to define the immunization needs of these groups. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
6. Impact of Adjuvants on the Immunogenicity and Efficacy of Split-Virion H7N9 Vaccine in Ferrets.
- Author
-
Keitel, Wendy A., Jackson, Lisa A., Edupuganti, Srilatha, Winokur, Patricia L., Mulligan, Mark J., Thornburg, Natalie J., Patel, Shital M., Rouphael, Nadine G., Lilin Lai, Bangaru, Sandhya, McNeal, Monica M., Bellamy, Abbie R., and Hill, Heather R.
- Subjects
INFLUENZA A virus, H3N2 subtype ,VIRUS disease transmission ,VIRAL disease treatment ,VIRAL vaccines ,IMMUNE response ,B cells ,IMMUNIZATION ,VACCINES - Abstract
Background. An effective vaccine is urgently needed against the H7N9 avian influenza virus. We evaluated the immunogenicity and protective efficacy of a split-virion H7N9 vaccine with or without the oil-in-water adjuvants in ferrets. Methods. Ferrets were vaccinated with 2 doses of unadjuvanted, MF59 or AS03-adjuvanted A/Shanghai/2/2013 (H7N9) vaccine, and the induction of antibodies to hemagglutinin (HA) or neuraminidase proteins was evaluated. Ferrets were then challenged with wild-type H7N9 virus to assess the vaccine's protective efficacy. The vaccine composition and integrity was also evaluated in vitro. Results. Adjuvanted vaccines stimulated robust serum antibody titers against HA and neuraminidase compared with the unadjuvanted vaccines. Although there was a difference in adjuvanticity between AS03 and MF59 at a lower dose (3.75 µg of HA), both adjuvants induced comparable antibody responses after 2 doses of 15 µg. On challenge, ferrets that received adjuvanted vaccines showed lower viral burden than the control or unadjuvanted vaccine group. In vitro examinations revealed that the vaccine contained visible split-virus particles and retained the native conformation of HA recognizable by polyclonal and monoclonal antibodies. Conclusions. The adjuvanted H7N9 vaccines demonstrated superior immunogenicity and protective efficacy against H7N9 infection in ferrets and hold potential as a vaccination regimen. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
7. Phase II randomized, double-blinded comparison of a single high dose (5×108 TCID50) of modified vaccinia Ankara compared to a standard dose (1×108 TCID50) in healthy vaccinia-naïve individuals.
- Author
-
Frey, Sharon E., Winokur, Patricia L., Hill, Heather, Goll, Johannes B., Chaplin, Paul, and Belshe, Robert B.
- Subjects
- *
ENZYME-linked immunosorbent assay , *RANDOMIZED controlled trials , *DRUG dosage , *SEROCONVERSION , *TITERS , *COMPARATIVE studies - Abstract
Highlights: [•] A single dose of high titer MVA vaccine was compared to 1 or 2 standard doses. [•] High dose MVA was safe and well-tolerated. [•] Median time to seroconversion was similar between the two groups. [•] ELISA and PRNT peak titers after 1 high dose were higher than 1 standard dose. [•] ELISA and PRNT peak titers after 1 high dose were inferior to 2 standard doses. [Copyright &y& Elsevier]
- Published
- 2014
- Full Text
- View/download PDF
8. Safety and immunogenicity of IMVAMUNE smallpox vaccine using different strategies for a post event scenario.
- Author
-
Frey, Sharon E., Winokur, Patricia L., Salata, Robert A., El-Kamary, Samer S., Turley, Christine B., Walter, Emmanuel B., Hay, Christine Mhorag, Newman, Frances K., Hill, Heather R., Zhang, Ying, Chaplin, Paul, Tary-Lehmann, Magdalena, and Belshe, Robert B.
- Subjects
- *
SMALLPOX vaccines , *VACCINE safety , *IMMUNOGENETICS , *BIOTERRORISM , *INF (Computer program language) , *IMMUNOGLOBULINS , *IMMUNE response , *DRUG dosage - Abstract
Highlights: [•] Reintroduction of Variola major as an agent of bioterrorism remains a concern. [•] A compressed schedule of MVA was evaluated for use in a post event scenario. [•] MVA is well tolerated when given as two standard doses at Days 0 and 28 or 0 and 7. [•] A 2nd dose of MVA at Day 28 compared to Day 7 provided greater antibody responses. [•] INF-γ expression was greatest within 2 weeks after last vaccination. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
9. Establishment of human post-vaccination SARS-CoV-2 standard reference sera.
- Author
-
Xiang, Jinhua, Katz, Louis, Winokur, Patricia L., Chaudhary, Ashok, Digmann, Barbara, Bradford, Rebecca, Rashid, Sujatha, Ghosh, Sudakshina, Robertson, Angela, Menetski, Joseph, Xu, Miao, Gao, Peng, Chen, Catherine Z., Lee, Taylor, Poelaert, Brittany, Eastman, Richard T., Hall, Matthew D., and Stapleton, Jack T.
- Subjects
- *
VIRAL envelope proteins , *COVID-19 vaccines , *SARS-CoV-2 , *BOOSTER vaccines , *VACCINE effectiveness - Abstract
There is a critical need to understand the effectiveness of serum elicited by different SARS-CoV-2 vaccines against SARS-CoV-2 variants. We describe the generation of reference reagents comprised of post-vaccination sera from recipients of different primary vaccines with or without different vaccine booster regimens in order to allow standardized characterization of SARS-CoV-2 neutralization in vitro. We prepared and pooled serum obtained from donors who received a either primary vaccine series alone, or a vaccination strategy that included primary and boosted immunization using available SARS-CoV-2 mRNA vaccines (BNT162b2, Pfizer and mRNA-1273, Moderna), replication-incompetent adenovirus type 26 vaccine (Ad26.COV2·S, Johnson and Johnson), or recombinant baculovirus-expressed spike protein in a nanoparticle vaccine plus Matrix-M adjuvant (NVX-CoV2373, Novavax). No subjects had a history of clinical SARS-CoV-2 infection, and sera were screened with confirmation that there were no nucleocapsid antibodies detected to suggest natural infection. Twice frozen sera were aliquoted, and serum antibodies were characterized for SARS-CoV-2 spike protein binding (estimated WHO antibody binding units/ml), spike protein competition for ACE-2 binding, and SARS-CoV-2 spike protein pseudotyped lentivirus transduction. These reagents are available for distribution to the research community (BEI Resources), and should allow the direct comparison of antibody neutralization results between different laboratories. Further, these sera are an important tool to evaluate the functional neutralization activity of vaccine-induced antibodies against emerging SARS-CoV-2 variants of concern. The explosion of COVID-19 demonstrated how novel coronaviruses can rapidly spread and evolve following introduction into human hosts. The extent of vaccine- and infection-induced protection against infection and disease severity is reduced over time due to the fall in concentration, and due to emerging variants that have altered antibody binding regions on the viral envelope spike protein. Here, we pooled sera obtained from individuals who were immunized with different SARS-CoV-2 vaccines and who did not have clinical or serologic evidence of prior infection. The sera pools were characterized for direct spike protein binding, blockade of virus-receptor binding, and neutralization of spike protein pseudotyped lentiviruses. These sera pools were aliquoted and are available to allow inter-laboratory comparison of results and to provide a tool to determine the effectiveness of prior vaccines in recognizing and neutralizing emerging variants of concern. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
10. Immunogenicity and safety of varying dosages of a fifth-wave influenza A/H7N9 inactivated vaccine given with and without AS03 adjuvant in healthy adults.
- Author
-
Jackson, Lisa A., Stapleton, Jack T., Walter, Emmanuel B., Chen, Wilbur H., Rouphael, Nadine G., Anderson, Evan J., Neuzil, Kathleen M., Winokur, Patricia L., Smith, Michael J., Schmader, Kenneth E., Swamy, Geeta K., Thompson, Amelia B., Mulligan, Mark J., Rostad, Christina A., Cross, Kaitlyn, Tsong, Rachel, Wegel, Ashley, and Roberts, Paul C.
- Subjects
- *
H7N9 Influenza , *IMMUNE response , *INFLUENZA , *VACCINES , *ANTIBODY titer , *INFLUENZA vaccines - Abstract
Human infections with the avian influenza A(H7N9) virus were first reported in China in 2013 and continued to occur in annual waves. In the 2016/2017 fifth wave, Yangtze River Delta (YRD) lineage viruses, which differed antigenically from those of earlier waves, predominated. In this phase 2 double-blinded trial we randomized 720 adults ≥ 19 years of age to receive two injections of a YRD lineage inactivated A/Hong Kong/125/2017 fifth-wave H7N9 vaccine, given 21 days apart, at doses of 3.75, 7.5, and 15 µg of hemagglutinin (HA) with AS03A adjuvant and at doses of 15 and 45 µg of HA without adjuvant. Two doses of adjuvanted vaccine were required to induce HA inhibition (HI) antibody titers ≥ 40 in most participants. After two doses of the 15 µg H7N9 formulation, given with or without AS03 adjuvant, the proportion achieving a HI titer ≥ 40 against the vaccine strain at 21 days after the second vaccination was 65 % (95 % CI, 57 %-73 %) and 0 % (95 % CI, 0 %-4%), respectively. Among those who received two doses of the 15 µg adjuvanted formulation the proportion with HI titer ≥ 40 at 21 days after the second vaccination was 76 % (95 % CI, 66 %-84 %) in those 19–64 years of age and 49 % (95 % CI, 37 %-62 %) in those ≥ 65 years of age. Responses to the adjuvanted vaccine formulations did not vary by HA content. Antibody responses declined over time and responses against drifted H7N9 strains were diminished. Overall, the vaccines were well tolerated but, as expected, adjuvanted vaccines were associated with more frequent solicited systemic and local adverse events. AS03 adjuvant improved the immune responses to an inactivated fifth–wave H7N9 influenza vaccine, particularly in younger adults, but invoked lower responses to drifted H7N9 strains. These findings may inform future influenza pandemic preparedness strategies. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
11. Point-of-Use Mixing of Influenza H5N1 Vaccine and MF59 Adjuvant for Pandemic Vaccination Preparedness: Antibody Responses and Safety. A Phase 1 Clinical Trial.
- Author
-
Mulligan, Mark J., Bernstein, David I., Frey, Sharon, Winokur, Patricia, Rouphael, Nadine, Dickey, Michelle, Edupuganti, Srilatha, Spearman, Paul, Anderson, Edwin, Graham, Irene, Noah, Diana L., Mangal, Brian, Kim, Sonnie, and Hill, Heather
- Subjects
AVIAN influenza A virus ,H5N1 Influenza ,VACCINE research ,VACCINATION ,IMMUNOGLOBULINS - Abstract
Background. Avian influenza A/H5N1 has threatened human health for nearly 2 decades. Avian influenza A vaccine without adjuvant is poorly immunogenic. A flexible rapid tactic for mass vaccination will be needed if a pandemic occurs.Methods. A multicenter, randomized, blinded phase 1 clinical trial evaluated safety and antibody responses after point-of-use mixing of influenza A/Indonesia/05/2005 (H5N1) vaccine with MF59 adjuvant. Field-site pharmacies mixed 3.75, 7.5, or 15 mcg of antigen with or without MF59 adjuvant just prior to intramuscular administration on days 0 and 21 of healthy adults aged 18–49 years.Results. Two hundred and seventy subjects were enrolled. After vaccination, titers of hemagglutination inhibition antibody ≥1:40 were achieved in 80% of subjects receiving 3.75 mcg + MF59 vs only 14% receiving 15 mcg without adjuvant (P < .0001). Peak hemagglutination inhibition antibody geometric mean titers for vaccine + MF59 were ∼65 regardless of antigen dose, and neutralizing titers were 2- to 3-fold higher. Vaccine + MF59 produced cross-reactive antibody responses against 4 heterologous H5N1 viruses. Excellent safety and tolerability were demonstrated.Conclusions. Point-of-use mixing of H5N1 antigen and MF59 adjuvant achieved target antibody titers in a high percentage of subjects and was safe. The feasibility of the point-of-use mixing should be studied further. [ABSTRACT FROM PUBLISHER]
- Published
- 2014
12. Tularemia vaccine: Safety, reactogenicity, “Take” skin reactions, and antibody responses following vaccination with a new lot of the Francisella tularensis live vaccine strain – A phase 2 randomized clinical Trial.
- Author
-
Mulligan, Mark J., Stapleton, Jack T., Keitel, Wendy A., Frey, Sharon E., Chen, Wilbur H., Rouphael, Nadine, Edupuganti, Srilatha, Beck, Allison, Winokur, Patricia L., El Sahly, Hana M., Patel, Shital M., Atmar, Robert L., Graham, Irene, Anderson, Edwin, El-Kamary, Samer S., Pasetti, Marcela F., Sztein, Marcelo B., Hill, Heather, and Goll, Johannes B.
- Subjects
- *
TULAREMIA , *IMMUNOGLOBULINS , *FRANCISELLA tularensis , *RANDOMIZED controlled trials , *CLINICAL trials , *VACCINATION - Abstract
Background Tularemia is caused by Francisella tularensis , a gram-negative bacterium that has been weaponized as an aerosol. For protection of personnel conducting biodefense research, the United States Army required clinical evaluation of a new lot of tularemia live vaccine strain manufactured in accordance with Current Good Manufacturing Practices. Methods A phase 2 randomized clinical trial compared the new lot (DVC-LVS) to the existing vaccine that has been in use for decades (USAMRIID-LVS). The vaccines were delivered by scarification to 228 participants. Safety, reactogenicity, take and/or antibody levels were assessed on days 0, 1, 2, 8, 14, 28, 56, and 180. Principal Results Both vaccines were safe and had acceptable reactogenicity profiles during six months of follow-up. There were no serious or grade 3 and 4 laboratory adverse events. Moderate systemic reactogenicity (mostly headache or feeling tired) was reported by ∼23% of participants receiving either vaccine. Injection site reactogenicity was mostly mild itchiness and pain. The frequencies of vaccine take skin reactions were 73% (95% CI, 64, 81) for DVC-LVS and 80% (95% CI, 71, 87) for USAMRIID-LVS. The 90% CI for the difference in proportions was −6.9% (−16.4, 2.6). The rates of seroconversion measured by microagglutination assay on days 28 or 56 were 94% (95% CI, 88, 98; n = 98/104) for DVC-LVS and 94% (95% CI, 87, 97; n = 103/110) for USAMRIID-LVS (p = 1.00). Day 14 sera revealed more rapid seroconversion for DVC-LVS relative to USAMRIID-LVS: 82% (95% CI, 73, 89) versus 55% (95% CI, 45, 65), respectively (p < 0.0001). Major conclusions The DVC-LVS vaccine had similar safety, reactogenicity, take and antibody responses compared to the older USAMRIID vaccine, and was superior for early (day 14) antibody production. Vaccination take was not a sensitive surrogate for seroconversion in a multi-center study where personnel at five research clinics performed assessments. ClinicalTrials.gov identifier NCT01150695 [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
13. Safety and immunogenicity of a modified vaccinia Ankara vaccine using three immunization schedules and two modes of delivery: A randomized clinical non-inferiority trial.
- Author
-
Jackson, Lisa A., Frey, Sharon E., El Sahly, Hana M., Mulligan, Mark J., Winokur, Patricia L., Kotloff, Karen L., Campbell, James D., Atmar, Robert L., Graham, Irene, Anderson, Evan J., Anderson, Edwin L., Patel, Shital M., Fields, Colin, Keitel, Wendy, Rouphael, Nadine, Hill, Heather, and Goll, Johannes B.
- Subjects
- *
SMALLPOX vaccines , *IMMUNOGENETICS , *CLINICAL trials , *DRUG administration , *ENZYME-linked immunosorbent assay , *ALLERGIES - Abstract
Introduction To guide the use of modified vaccinia Ankara (MVA) vaccine in response to a release of smallpox virus, the immunogenicity and safety of shorter vaccination intervals, and administration by jet injector (JI), were compared to the standard schedule of administration on Days 1 and 29 by syringe and needle (S&N). Methods Healthy adults 18–40 years of age were randomly assigned to receive MVA vaccine subcutaneously by S&N on Days 1 and 29 (standard), Days 1 and 15, or Days 1 and 22, or to receive the vaccine subcutaneously by JI on Days 1 and 29. Blood was collected at four time points after the second vaccination for plaque reduction neutralization test (PRNT) (primary endpoint) and ELISA (secondary endpoint) antibody assays. For each subject, the peak PRNT (or ELISA) titer was defined by the highest PRNT (or ELISA) titer among all available measurements post second vaccination. Non-inferiority of a non-standard arm compared to the standard arm was met if the upper limit of the 98.33% confidence interval of the difference in the mean log 2 peak titers between the standard and non-standard arm was less than 1. Results Non-inferiority of the PRNT antibody response was not established for any of the three non-standard study arms. Non-inferiority of the ELISA antibody response was established for the Day 1 and 22 compressed schedule and for administration by JI. Solicited local reactions, such as redness and swelling, tended to be more commonly reported with JI administration. Four post-vaccination hypersensitivity reactions were observed. Conclusions Evaluations of the primary endpoint of PRNT antibody responses do not support alternative strategies of administering MVA vaccine by S&N on compressed schedules or administration by JI on the standard schedule. Trial Registration: clinicaltrials.gov Identifier: NCT01827371 . [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
14. Comparison of the immunogenicity and safety of a split-virion, inactivated, trivalent influenza vaccine (Fluzone®) administered by intradermal and intramuscular route in healthy adults
- Author
-
Frenck, Robert W., Belshe, Robert, Brady, Rebecca C., Winokur, Patricia L., Campbell, James D., Treanor, John, Hay, Christine M., Dekker, Cornelia L., Walter, Emmanuel B., Cate, Thomas R., Edwards, Kathryn M., Hill, Heather, Wolff, Mark, LeDuc, Tom, and Tornieporth, Nadia
- Subjects
- *
INFLUENZA vaccines , *DRUG administration , *VIRION , *COMPARATIVE studies , *DOSAGE forms of drugs , *IMMUNE response , *HEMAGGLUTINATION tests , *INTRADERMAL injections - Abstract
Abstract: The aim of the study was to determine whether reduced doses of trivalent inactivated influenza vaccine (TIV) administered by the intradermal (ID) route generated similar immune responses to standard TIV given intramuscularly (IM) with comparable safety profiles. Recent changes in immunization recommendations have increased the number of people for whom influenza vaccination is recommended. Thus, given this increased need and intermittent vaccine shortages, means to rapidly expand the vaccine supply are needed. Previously healthy subjects 18–64 years of age were randomly assigned to one of four TIV vaccine groups: standard 15μg HA/strain TIV IM, either 9μg or 6μg HA/strain of TIV ID given using a new microinjection system (BD Soluvia™ Microinjection System 1 [1] BD Soluvia™ is the trademark of BD micro-injection system, Becton Dickinson (BD), BD Medical Pharmaceutical Systems. ), or 3μg HA/strain of TIV ID given by Mantoux technique. All vaccines contained A/New Caledonia (H1N1), A/Wyoming (H3N2) and B/Jiangsu strains of influenza. Sera were obtained 21 days after vaccination and hemagglutination inhibition (HAI) assays were performed and geometric mean titers (GMT) were compared among the groups. Participants were queried immediately following vaccination regarding injection pain and quality of the experience. Local and systemic reactions were collected for 7 days following vaccination and compared. Ten study sites enrolled 1592 subjects stratified by age; 18–49 years [N =814] and 50–64 years [N =778]. Among all subjects, for each of the three vaccine strains, the GMTs at 21 days post-vaccination for both the 9μg and the 6μg doses of each strain given ID were non inferior to GMTs generated after standard 15μg doses/strain IM. However, for the 3μg ID dose, only the A/Wyoming antigen produced a GMT that was non-inferior to the standard IM dose. Additionally, in the subgroup of subjects 50–64 years of age, the 6μg dose given ID induced GMTs that were inferior to the standard IM TIV for the A/H1N1 and B strains. No ID dose produced a GMT superior to that seen after standard IM TIV. Local erythema and swelling were significantly more common in the ID groups but the reactions were mild to moderate and short-lived. No significant safety issues related to intradermal administration were identified. Participants given TIV ID provided favorable responses to questions about their experiences with ID administration. In conclusion, for the aggregated cohorts of adults 18–64 years of age, reduced doses (6μg and 9μg) of TIV delivered ID using a novel microinjection system stimulated comparable HAI antibody responses to standard TIV given IM. The reduced 3μg dose administered ID by needle and syringe, as well as the 6μg ID for subjects aged 50–64 years of age generated poorer immune responses as compared to the 15μg IM dose. [Copyright &y& Elsevier]
- Published
- 2011
- Full Text
- View/download PDF
15. Immunogenicity, safety and consistency of new trivalent inactivated influenza vaccine
- Author
-
Talbot, H. Keipp, Keitel, Wendy, Cate, Thomas R., Treanor, John, Campbell, James, Brady, Rebecca C., Graham, Irene, Dekker, Cornelia L., Ho, Dora, Winokur, Patricia, Walter, Emmanuel, Bennet, Jillian, Formica, Neil, Hartel, Gunter, Skeljo, Maryanne, and Edwards, Kathryn M.
- Subjects
- *
INFLUENZA vaccines , *INFLUENZA viruses , *PLACEBOS , *VACCINATION - Abstract
Abstract: To augment the available influenza vaccine supply, a phase III study was conducted to evaluate the immunogenicity, safety, and consistency of a new trivalent inactivated influenza vaccine manufactured by CSL Limited. Healthy adults (ages 18–64) were randomized to receive either a single dose of TIV from multi-dose vials with thimerosal, TIV from pre-filled syringes without thimerosal, or placebo. Of the TIV recipients, 97.8% achieved a post-vaccination titer ≥40 against H1N1, 99.9% against H3N2 component, and 94.2% against influenza B. Few local or systemic adverse events were noted after vaccination with either TIV presentation. TIV was well tolerated and immunogenic. [Copyright &y& Elsevier]
- Published
- 2008
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.